Long-acting APRETUDE was proven superior at reducing the risk of getting HIV vs once-daily TRUVADA
Randomized, double-blind, controlled clinical trials were used to make the results of the study less likely to be biased.
In these clinical trials, participants were randomly assigned to receive either APRETUDE + TRUVADA placebo or TRUVADA + APRETUDE placebo.
Neither participants nor investigators knew which medicine participants were receiving.
More people stayed HIV negative on APRETUDE than on TRUVADA during the studies.
Among the most diverse PrEP studies ever conducted
Study 1: 4,566 HIV-1—negative cisgender men and transgender women at risk for getting HIV
- On APRETUDE: 12 out of 2,278 people became HIV positive
- On TRUVADA: 39 out of 2,281 people became HIV positive
Significantly more people stayed HIV negative on APRETUDE vs TRUVADA during the study
Participants were on the product for a median of 1.3 years.
Results may vary.
Most Common Side Effect
The most common side effect reported in participants receiving APRETUDE in Study 1 was injection site reactions (82%). This is not the only side effect of APRETUDE. For more information, see the Risks & Side Effects page. Always tell your doctor if you experience any side effect.
After this portion of the study, participants were surveyed
When the trial was complete, participants were offered the choice of continuing the study with APRETUDE or TRUVADA. Of the 1,698 participants originally included from the US, 803 (47%) had preference data available. Individuals preferring an oral PrEP option may have chosen to not enroll in the study.
In Study 1
Study 2: 3,224 HIV-1—negative cisgender women at risk for getting HIV
- On APRETUDE: 3 out of 1,613 people became HIV positive
- On TRUVADA: 36 out of 1,610 people became HIV positive
Significantly more women stayed HIV negative on APRETUDE vs TRUVADA during the study
Participants were on the product for a median of 1.2 years.
Results may vary.
Most Common Side Effects
The most common side effects reported in participants receiving APRETUDE in Study 2 were injection site reactions (38%) and headache (12%). These are not the only side effects of APRETUDE. For more information, see the Risks & Side Effects page. Always tell your doctor if you experience any side effect.
After this portion of the study, participants were surveyed
When the trial was complete, participants were offered the choice of continuing the study with APRETUDE or TRUVADA. Of the 3,028 patients in the study, 2,472 (81%) had preference data available. Individuals preferring an oral PrEP option may have chosen to not enroll in the study.
In Study 2
APRETUDE is given every other month by a healthcare provider after initiation injections have been given 1 month apart for 2 consecutive months. Stay under a provider’s care while receiving APRETUDE. You must receive it as scheduled. If you will miss a scheduled injection by more than 7 days, call your provider right away.
Eligible patients may pay as little as a $0 copay
per injection on prescribed APRETUDE.*
*Terms and conditions apply
PMUS-CBTWCNT240059